Radiofrequency combined with ultrasound for postpartum sexual pain
Official title: Effectiveness of Combined Monopolar Radiofrequency and Ultrasound (BTL EXILIS ULTRA 360™) for the Improvement of Dyspareunia Caused by Postpartum Scarring in Women of Childbearing Age: A Study Protoco
Run by Institut Investigacio Sanitaria Pere Virgili · NCT07504991 · Data updated 2026-11-12
This study will try a combined radiofrequency and ultrasound treatment (BTL Exilis) to reduce pain during sex in women who developed dyspareunia after a vaginal delivery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 50 Years |
| Sex | Women only |
| Enrollment | 34 (estimated) |
| Sponsor | Institut Investigacio Sanitaria Pere Virgili Academic / other |
| Locations | 1 site (Tarragona, TARRAGONA) |
| Status | Recruiting |
| Started | April 2026 |
| Main results expected | July 1, 2026 |
| Study ends | December 2026 |
| Registry record updated | April 16, 2026 |
| Trial ID | NCT07504991 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women of childbearing age with at least one prior vaginal delivery involving a tear or episiotomy, persistent moderate-to-severe dyspareunia (VAS ≥4), and no contraindications to radiofrequency/ultrasound are ideal candidates.
✕Probably not a fit
Patients with non-postpartum causes of dyspareunia, mild pain (VAS <4), underlying pelvic pathology causing pain, or medical contraindications to the device are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a community-based, non-randomized, quasi-experimental study delivering monopolar radiofrequency combined with ultrasound (BTL Exilis) to women with dyspareunia following at least one vaginal delivery that involved a tear or episiotomy. Pain during penetrative intercourse will be measured before and after treatment in the same individuals using the Visual Analogue Scale (VAS), with moderate-to-severe pain defined as VAS ≥4. There is no randomized control group; the primary outcome is resolution or reduction of pain during sexual intercourse after completing the treatment. The trial is conducted at Centro Procrear in Tarragona and requires informed consent and clinical confirmation of postpartum dyspareunia.
Why it matters
Potential benefit: If successful, the treatment could reduce or eliminate pain during intercourse and improve sexual function and quality of life for affected women.
How similar studies have gone: Energy-based vaginal therapies including radiofrequency have been used for vaginal laxity and sexual symptoms with mixed and limited high-quality evidence, and specific data for postpartum dyspareunia are sparse.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women of childbearing age * Medical history of at least one prior vaginal delivery * Reported persistent pain during penetrative sexual intercourse * Meeting the clinical criteria for dyspareunia * Moderate to severe pain level, defined as a score of 4 or higher on the Visual Analogue Scale (VAS 0-10) * Eligible patients must demonstrate a moderate to severe pain level, defined as a VAS score of 4 or higher * No restriction on the time elapsed between the last delivery and the current clinical diagnosis. Exclusion Criteria: * Contraindications to the study treatment. Women with any medical condition that precludes the use of the study technology * Non-postpartum dyspareunia
Where it's running
-
Centro Procrear
Tarragona, Tarragona, Spain Recruiting
Study contacts
- Principal investigator: Lys Garcia Vilaplana, Midwife. Phd Student — Universitat Rovira I Virgili. Procrear Medical Center
- Study coordinator: LYS GARCIA VILAPLANA, Lead Researcher
- Email: lys@procrear.es
- Phone: +34619357158
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sexual Health in Spanish-Speaking Adults: A Large Online Survey
A large online survey will test sexual health, sexual behavior, and sexual function in Spanish-speaking adults to see how common these experiences are and to explore unusual states of consciousness during orgasm.
-
F-GYN injection for vaginal dryness and vaginal/vestibular atrophy
This study tests whether a one-time F-GYN injection can relieve vaginal dryness and related symptoms in adult women with atrophic vaginitis/vestibulovaginal atrophy compared with standard non-hormonal care.
-
Nonhormonal vulvovaginal gel to relieve menopausal vulvovaginal symptoms
This will test a hormone-free vulvovaginal gel in postmenopausal women with genitourinary syndrome of menopause to see if it reduces vaginal atrophy symptoms and improves daily quality of life.
-
Using tDCS stimulation to improve function and reduce pain in neurological and gynaecological patients
This study is testing if a brain stimulation treatment can help improve movement and reduce pain for people with neurological and gynecological conditions.
-
Comparing a vibrating pelvic floor device to traditional vaginal dilators for treating entry dyspareunia
This study is testing whether a new vibrating pelvic floor device can help women with pain during sex feel better compared to using traditional vaginal dilators.
-
Telerehabilitation program for improving sexual function and reducing pain in menopausal women
This study is testing a telerehabilitation program to see if it can help menopausal women with painful sex feel better and improve their overall quality of life compared to regular in-person therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.